Word

PEMPFIX

Status

Registered

Status Code

700

Status Date

Tuesday, April 10, 2018

Serial Number

79212465

Registration Number

5440650

Registration Date

Tuesday, April 10, 2018

Mark Type

4000

Filing Date

Thursday, June 2, 2016

Published for Opposition

Tuesday, January 23, 2018

Trademark Owner History

Novalis Investments S.L. -
Immungenetics AG - Original Registrant

Classifications

5 Pharmaceutical and biochemical pharmaceutical preparations for the treatment of or prevention against inflammatory diseases, cancer, infectious diseases, fungal diseases, diseases caused by parasites, eye diseases, diseases of the central and peripheral nervous systems, cardiovascular diseases, diseases affecting the immune system, genetic diseases, single gene disorders, mouth, teeth, skin, hair and ear diseases, bone and blood diseases as well as reproductive system diseases; pharmaceutical and biochemical pharmaceutical preparations for contraception; biochemical and chemical pharamceuticals preparations for use with inflammatory diseases, in particular for use with chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against inflammatory diseases, in particular for prevention against chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory skin diseases; biochemical and chemical products for prevention against psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for prevention against blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus diseases; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceuticals preparations for prevention against subepidermal bullous autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoide, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory diseases of the central nervous systems, in particular for prevention against multiple sclerosis; biochemical and chemical pharmaceuticals preparations for the treatment of inflammatory diseases, in particular for the treatment of chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory skin diseases, in particular for the treatment of psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for the treatment of blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus diseases; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceutical preparations for the treatment of subepidermal bullae autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoid, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory diseases of the central nervous system, in particular for the treatment of multiple sclerosis; topical and transdermal pharmaceuticals, in particular creams, dispersions, lotions, ointments, fluids, solutions, sprays, plasters, lacquer and filmforming solutions, for the prevention and treatment of skin diseases of the uppermost skin layer or the upper skin layers; surface treatment pharmaceuticals preparations for use as treatments of immune system diseases, inflammatory diseases, skin, hair and ear diseases; oral administration pharmaceuticals preparations, in particular pills, tablets, lozenges, capsules, liquids, solutions, drops, for the prevention and treatment of central nervous system diseases

The word(s) "PEMPIX" has no meaning in a foreign language.

Trademark Events

Apr 10, 2023

Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed

Jul 30, 2021

New Representative At Ib Received

Apr 30, 2020

Change Of Owner Received From Ib

Jul 26, 2019

New Representative At Ib Received

Aug 24, 2018

Final Decision Transaction Processed By Ib

Jul 30, 2018

Final Disposition Notice Sent To Ib

Jul 30, 2018

Final Disposition Processed

Jul 10, 2018

Final Disposition Notice Created, To Be Sent To Ib

Apr 10, 2018

Registered-Principal Register

Feb 21, 2018

Teas Change Of Correspondence Received

Jan 23, 2018

Published For Opposition

Jan 19, 2018

Notification Processed By Ib

Jan 3, 2018

Notification Of Possible Opposition Sent To Ib

Jan 3, 2018

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Jan 3, 2018

Notice Of Publication

Dec 19, 2017

Approved For Pub - Principal Register

Nov 27, 2017

Teas/Email Correspondence Entered

Nov 27, 2017

Correspondence Received In Law Office

Nov 19, 2017

Assigned To Lie

Nov 8, 2017

Teas Response To Office Action Received

Aug 18, 2017

Refusal Processed By Ib

Aug 1, 2017

Non-Final Action Mailed - Refusal Sent To Ib

Aug 1, 2017

Refusal Processed By Mpu

Aug 1, 2017

Non-Final Action (Ib Refusal) Prepared For Review

Jul 31, 2017

Non-Final Action Written

Jul 25, 2017

Application Filing Receipt Mailed

Jul 19, 2017

Assigned To Examiner

Jul 19, 2017

New Application Office Supplied Data Entered

Jul 13, 2017

Sn Assigned For Sect 66a Appl From Ib